Skip to main content

ICH Q8 (R2) Pharmaceutical development (CHMP/ICH/167068/04)

 ICH Q8 (R2) is a guideline titled "Pharmaceutical Development" (CHMP/ICH/167068/04). This guideline is part of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and provides recommendations for the pharmaceutical development of medicinal products. It offers a structured approach to the development of pharmaceutical products to ensure their quality, safety, and efficacy. Here's an elaboration of ICH Q8 (R2):


1. Purpose of ICH Q8 (R2):

The primary purpose of ICH Q8 (R2) is to provide a systematic and science-based approach to pharmaceutical development. The guideline aims to facilitate the design and development of high-quality pharmaceutical products that meet the needs of patients and regulatory authorities.

2. Scope:

ICH Q8 (R2) applies to the development of all types of pharmaceutical products, including small molecules, biotechnological products, and other complex medicinal products.

3. Pharmaceutical Development Principles:

The guideline emphasizes a quality-by-design (QbD) approach to pharmaceutical development. This means that product quality is built into the development process from the beginning, with a focus on understanding and controlling the critical quality attributes (CQAs) of the product.

4. Quality Target Product Profile (QTPP):

Manufacturers are encouraged to define a Quality Target Product Profile (QTPP) early in the development process. The QTPP outlines the desired quality characteristics of the product and serves as a guide throughout development.

5. Risk Assessment:

Risk assessment is a fundamental component of ICH Q8 (R2). Manufacturers should identify and assess potential risks to product quality, safety, and efficacy and develop strategies to mitigate these risks.

6. Pharmaceutical Development Studies:

The guideline emphasizes the need for systematic pharmaceutical development studies to understand and control the variables that can impact product quality. These studies may include formulation development, process development, and analytical method development.

7. Design of Experiments (DoE):

Design of Experiments (DoE) is a statistical approach recommended for optimizing and controlling processes. It allows for the systematic study of variables and their impact on product quality.

8. Lifecycle Approach:

ICH Q8 (R2) promotes a lifecycle approach to pharmaceutical development. This means that development activities continue throughout the product's lifecycle, including post-approval phases.

9. Regulatory Considerations:

Regulatory authorities encourage early dialogue between manufacturers and regulators to discuss development plans and strategies. Transparency and collaboration with regulatory agencies are important aspects of this guideline.

10. Control Strategy:

- Manufacturers should develop a control strategy that includes specifications for CQAs, critical process parameters (CPPs), and critical material attributes (CMAs). The control strategy ensures that the product consistently meets its intended quality attributes.

11. Regulatory Filing:

- The data generated during pharmaceutical development, including information on formulation, manufacturing processes, and analytical methods, should be included in regulatory submissions to support marketing authorization.

12. Post-Approval Changes:

- The guideline recognizes that post-approval changes to a product may occur and emphasizes the importance of assessing the impact of changes on product quality and regulatory requirements.


In summary, ICH Q8 (R2) provides a structured and science-based approach to pharmaceutical development, with an emphasis on quality by design, risk assessment, and a lifecycle perspective. Compliance with these principles helps ensure that pharmaceutical products are developed and manufactured with a strong focus on quality, safety, and efficacy, leading to better patient outcomes and regulatory approval.

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

SOP on Investigator Delegation of Authority

Title: Investigator Delegation of Authority Introduction and Purpose: This Standard Operating Procedure (SOP) outlines the process by which the Principal Investigator (PI) delegates the authority to conduct clinical study procedures and tasks to sub-investigators and other study personnel. It also details the maintenance of documentation related to staff and investigator signatures and handwriting samples. Scope: The PI conducting a clinical trial must adhere to regulations governing informed consent (21 CFR 50) and regulations regarding Institutional Review Board (IRB) review and approval (21 CFR 56). If the study involves an investigational drug or device, additional regulations in 21 CFR 312 or 21 CFR 812 apply. Furthermore, all clinical study investigators should follow the International Council on Harmonization (ICH) guidelines for Good Clinical Practice (GCP). While these responsibilities are primarily held by the PI, they can be delegated to qualified sub-investigators and other...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more